CRDF - Cardiff Oncology, Inc.
Cardiff Oncology, Inc. , a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.
As of May 15, 2026: spot at $1.67, ATM IV 187.4%, net GEX $7.7K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $115.5M
- Beta
- 1.36
- 52-Week Range
- 1.48-4.56
- CEO
- Mani Mohindru
- Employees
- 32
- IPO Date
- Jul 27, 2004
- Exchange
- NASDAQ
What CRDF Looks Like to Options Traders Today
IV rank of 33.7% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; positive net gamma exposure ($7.7K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.177) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The CRDF overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked CRDF overview questions
- What is CRDF?
- CRDF is the ticker symbol for Cardiff Oncology, Inc., a listed security. Cardiff Oncology, Inc. , a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Listed on NASDAQ. CRDF is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the CRDF options snapshot look like today?
- As of May 15, 2026, the CRDF options snapshot shows spot at $1.67, ATM IV 187.4%, IV rank 33.7%, net GEX $7.7K, expected move 53.73%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are CRDF's key statistics?
- Cardiff Oncology, Inc. (CRDF) carries a market capitalization of $115.5M, beta of 1.36 relative to the broader market, 52-week range of 1.48-4.56. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does CRDF belong to?
- Cardiff Oncology, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare CRDF's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the CRDF data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).